Women who drank at least two cups of tea a day had a lower risk of ovarian cancer than those who did not drink tea, according to a study in the December 12/26 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
Evidence from laboratory studies indicates that green and black tea preparations may protect against various cancers. But few epidemiological studies have examined the relationship specifically between tea consumption and the risk of ovarian cancer, according to background information in the article.
Susanna C. Larsson, M.Sc., and Alicja Wolk, D.M.Sc., of the National Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, prospectively examined the association between tea consumption and the risk of ovarian cancer in 61,057 women, aged 40 to 76, who were participants in the population-based Swedish Mammography Cohort. Participants completed a validated 67-item food frequency questionnaire at enrollment between 1987 and 1990, and were followed for cancer incidence through December 2004. At baseline, 68 percent of the participants reported drinking tea (mainly black tea) at least once per month. During an average follow-up of 15.1 years, 301 women were diagnosed as having invasive epithelial ovarian cancer.
"We observed a 46 percent lower risk of ovarian cancer in women who drank two or more cups of tea per day compared with non-drinkers," the authors report. "Each additional cup of tea per day was associated with an 18 percent lower risk of ovarian cancer."
Women who drank less than one cup of tea per day had an 18 percent lower risk of ovarian cancer than non-drinkers. The risk was 24 percent lower for women who drank one cup of tea per day.
"This association does not depend on lower coffee consumption among women with high tea consumption; coffee is not associated with ovarian cancer risk in this cohort," the authors write.
"In summary, our results from a large population-based cohort of Swedish women suggest that tea consumption may lower the risk of ovarian cancer," the authors conclude. "Because prospective data on this relationship are scarce, our findings need confirmation by future studies."
(Arch Intern Med. 2005;165:2683-2686. Available pre-embargo to the media at www.jamamedia.org.)
Editor's Note: This work was supported by research grants from the Swedish Cancer Foundation and the Swedish Research Council/Longitudinal Studies, Stockholm, Sweden.
Risk of ovarian cancer, according to background information in the article.
This present report describes the treatment of a laryngeal squamous cell carcinoma patient with the water-soluble artemisinin analog, artesunate. Artemisinin is a novel anti-cancer drug with demonstrated results in killing cancer cells. Artesunate injections and tablets were administered to the patient over a period of nine months. The tumor was significantly reduced (by 70%) after two months of treatment. Overall, the arte- sunate treatment of the patient was beneficial in prolonging and improving the quality of life. Artemisinin and its analogs offer promise for cancer therapy.
Approximately one percent of all cancers originates in the larynx and laryngeal cancer comprises 45% of the carcinomas of the head and neck (1). The majority of laryngeal carcinomas are squamous cell carcinoma. Cancer of the larynx is most often found in males over the age of 50. It is often associ- ated with heavy tobacco and alcohol use. The most common treatment options for laryngeal cancer patients are radiation ther- apy, surgery and chemotherapy.
In this case report, we implemented a novel therapy for the treat- ment of laryngeal cancer using artesunate, an analog of the anti- malarial drug artemisinin. Artemisinin is a sesquiterpene lactone, isolated from the plant Artemisia annua L. (sweet wormwood). The artemisinin molecule contains an endoperoxide bridge that reacts with an iron atom to form free radicals (2), which causes macromolecular damage and cell death. Since cancer cells have a significantly higher iron influx via the transferrin receptor mech- anism, they should be more susceptible to the cytotoxic effect of artemisinin. The anti-cancer potential of an analog of artemisinin has been studied in vitro with promising results (3,4). This report is the first on the use of artemisinin as an anti-cancer therapy in humans.
A seventy-two year old vegetarian male with a long history of tobacco chewing and smoking was admitted to Vivekanand Hospital (Meerut, India) on December 15, 2000. The patient com- plained of progressive hoarseness, and loss of appetite and weight for the last eight months. For the last six months, he noticed a periodic difficulty in swallowing solid food that increased with time. Four months before coming to the clinic, the patient noticed pain in the right ear. The pain was piercing, of moderate intensity, and intermittent without any radiation. Two months prior to admission, he also noticed pain in the right side of neck below the mandible. This pain was of mild intensity, inter- mittent, and without any radiation. The patient was unable to swal- low food 15 days before admission. As soon as he took solid food, it was immediately vomited out with a coughing reflex. The vomitus was blood stained. On the day of admission, the patient showed: 1) significant difficulty in swallowing of solid food; 2) hoarseness of voice; and 3) complaint of pain in the right ear and the right side of neck below the mandible. Physical examination revealed enlarged cervical lymph nodes on the right side of the neck. Laryngoscopic examination showed a growth on the right side of the larynx. The growth was covering the right vocal cord, right pyriform fossa, ventral aspect of epiglottis, and adjacent area of the lateral pharyngeal wall. The surface of the growth was irreg- ular, nodular, ulcerated and bled on touch. Its size was approxi- mately 3 cm x 2.5 cm x 3 cm=22.5 cm3. The diagnosis was a stage II cancer of the larynx (T2 N1 M0). A diagnosis of differen- tiated squamous cell carcinoma was established after histopatho- logical examination of a biopsy from the growth.
After obtaining consent from the patient, artesunate treatment was started on 01/22/2001. On day one of treatment, a capsule containing ferrous sulfate (150 mg) and folic acid (0.5 mg) was given orally at 2:00 PM after a meal. Injections of artesunate (60 mg I.M. per day; Cadila Healthcare Ltd., Ahmedabad, India) were given from day one (01/22/2001) to day 15 (02/05/2001) at 10:00 PM of each day. One tablet of artesunate (50 mg; Cadila Healthcare Ltd., Ahmedabad, India) was taken orally at 10:00 PM after the evening meal every day from day 16 (02/06/2001) onward. The patient had been doing weight-bearing exercises since the treatment began. More details regarding the therapy can be obtained by contacting the first author.
The patient had a fever (100-101ˇF) from day four to day seven of the treatment. After starting the treatment his hoarseness of voice gradually reduced. Within two weeks of the treatment, his voice became clear. The patient was able to take solid foods quite comfortably. He regained a good appetite. Clinical examination revealed cervical lymph nodes were reduced in size. Laryngoscopic examination on 03/25/2001 showed a growth involving the right vocal cord, right pyriform fossa, and ventral aspect of epiglottis and adjacent lateral pharyngeal wall. The size of the growth was approximately 2.25 cm x 2 cm x 1.5 cm=6.75 cm3, which was significantly reduced by 70% from its original size (22.5 cm3 - 6.75 cm3 = 15.75 cm3, this equals a reduction of 70%). The growth was non-nodular and non-ulcerating. The patient gained two kilograms of weight in the two months since starting the treatment and felt physically and mentally strong. In an unrelated note, the patients had extensive patches of leuko- derma around his mouth, on fingers of both hands, which responded well to artesunate treatment over the nine months of observation.
This is the first report on the use of a daily dose of artesunate for cancer treatment. We have previously reported that artemisinin selectively killed MOLT-4 lymphoblastoid cells (a human leukemia cell line) after incubation with holotransferrin (3), whereas the same treatment had significantly less effect on nor- mal human lymphocytes. A similar effect was observed in human breast cancer cells (4). Furthermore, we found that oral adminis- tration of an artemisinin analog and ferrous sulfate retarded the growth of implanted fibrosarcoma tumors in the rat (5). A more recent study has also shown that artesunate can effectively retard the growth of various types of human cancer cells in vitro (6). Without treatment, laryngeal cancer patients die within an average of 12 months (1). The patient lived for nearly one year and eight months (until his death on 1/11/02 due to pneumonia) after the appearance of symptoms, although treatment was discontinued after nine months. Considering the complicating factors in this case, including the discontinuation of treatment and the late stage diagnosis, we feel artemisinin was successful in both prolonging and improving the quality of the patient's life.
The observations that the patient regained his voice, appetite, and weight after a short term treatment with artesunate and the fact that the tumor significantly reduced in size (by 70%), where- as no apparent adverse side effect was observed, indicate that this can be an effective and economical alternative treatment for cancer, especially in cases of late detection where available treat- ments are limited. Since this case, several patients with different types of cancers have begun treatment with artemisinin and its analogs with promising results. We feel that this emerging new therapy has promise to prevent and treat different types of can- cers since it works via a simple mechanism which is common to all cancer cells (i.e. an increase in iron influx).
The authors are grateful to Miss Himani Singh for her help in preparation of the manuscript.
Assess the efficacy of a 10-week consumption of guava juice on the iron status of children with mild iron deficiency anemia.
Ninety-five boarding school children aged 6-9 years identified as anemic were randomly allocated to receive 300 mL of natural guava juice containing ∼200 mg of ascorbic acid (AA) or placebo (guava-flavored juice free of AA) with the main meal (5 d/wk). Information about dietary intake was collected at weeks 3, 5, and 7 at school and household levels. Changes in hemoglobin (Hb) and plasma ferritin (PF) among the subsample iron deficient at baseline (n = 33) were the main outcomes.
Iron and phytic acid intakes at school and at home did not differ between groups. Baseline Hb and PF were 11.9 ± 0.5 g/dL and 8.2 ± 3.6 ng/mL for the guava, and 11.4 ± 1.1 g/dL and 7.4 ± 4.6 ng/mL for the placebo group (Hb: p = 0.08; PF: p = 0.31); at week 10 of the study, corresponding values were 13.1 ± 0.9 g/dL and 17.9 ± 10.3 ng/mL (n = 16), and 12.3 ± 1.3 g/dL and 15.4 ± 5.8 ng/mL (n = 12) (Hb: p = 0.05; PF: p = 0.21). With analysis of variance (ANOVA) for repeated measures, the guava group had 0.64 g/dL higher Hb (CI(95), 0.18-1.11; p = 0.01) and 2.47 ng/mL higher PF (CI(95), -1.04 to 5.98; p = 0.12) compared with the placebo group.
Guava juice providing 200 mg AA at one meal on each school day had a marginal effect on Hb and PF concentrations in children consuming high-phytate diets fortified with iron.
Iron deficiency anemia has occurred more frequently in female than male regular blood donors. Iron supplement is necessary for maintaining the hemoglobin level. A combination with ascorbic acid increases the absorption of iron.
Compare the effect of ferrous fumarate 200 mg/day and the combination of ferrous fumarate 200 mg/day with ascorbic acid 100 mg/day and 500 mg/day on hemoglobin level and red blood cell indices in female regular blood donors.
MATERIAL AND METHOD:
Female regular blood donor volunteers were randomly divided into three equal groups to supplement with each regimen for one month. Hemoglobin (Hb), MCV, MCH, and MCHC before and after blood donation at 0.5, 1, 2, and 3 months, were compared.
Ninety-six volunteers were included and equally divided into three groups of 32 volunteers each. There were no significant differences between age, BMI, ABO blood group, Rh, Hb, MC, MCH, and MCHC before blood donation between each group (p > 0.05). The duration of recovery times of Hb to before blood donation levels in group I, II, and III being 2, 3, and 1 month, respectively were statistically significant difference (p < 0.001). The duration of recovery times of MCV, MCH, and MCHC to before blood donation levels in both group II and III were similar (0.5 months in every value), which was more rapid than in group I (> 3, 3, and 1 month, respectively) with statistically significant difference (p < 0.001). All three groups tolerated well. No participant withdrew from the present study because of side effects.
The present study shows that a combination of ferrous fumarate 200 mg and ascorbic acid 500 mg per day accelerates timing of hemoglobin and red blood cell indices in recovery to the level of before blood donation in female regular blood donors.
Ganoderma lucidum (Lingzhi or Reishi) is known as a bitter mushroom with remarkable health benefits. The active constituents found in mushrooms include polysaccharides, dietary fibers, oligosaccharides, triterpenoids, peptides and proteins, alcohols and phenols, mineral elements (such as zinc, copper, iodine, selenium, and iron), vitamins, and amino acids. The bioactive components found in the G. lucidum mushroom have numerous health properties to treat diseased conditions such as hepatopathy, chronic hepatitis, nephritis, hypertension, hyperlipemia, arthritis, neurasthenia, insomnia, bronchitis, asthma, gastric ulcers, atherosclerosis, leukopenia, diabetes, anorexia, and cancer. In spite of the voluminous literature available, G. lucidum is used mostly as an immune enhancer and a health supplement, not therapeutically. This review discusses the therapeutic potential of G. luidum to attract the scientific community to consider its therapeutic application where it can be worth pursuing.